Objective: Chronic allergic asthma (CA) is a respiratory disease that affects millions of people worldwide. While there is evidence linking airway hyperresponsiveness and asthma to factors related to bone metabolism, the impact of asthma on bone health is not well understood. Therefore, to explore whether: (i) CA causes meaningful changes in bone magnesium (Mg) and selenium (Se) levels, and if any, (ii) anti-IgE (anti-immunoglobulin E) treatment has a protective effect against these changes.
Methods: In present study used tibia bones from a previous study on CA in mice. A murine model was used to generate CA. Thirty-two BALB/c male mice were randomly divided into four equal sized groups (eight mice/group): control group (intact), CA (treated with saline (0.9% NaCl), CA+L-AIgE (100 μg of anti-IgE), CA+H-AIgE (200 μg of anti-IgE). After immunization, saline was administered by inhalation three times a week. Anti-IgE applications were performed intraperitoneally for a total of 8 weeks in five sessions with 15-day intervals. Bone Mg and Se levels are determined by inductively coupled plasma mass spectrometry (ICP-MS), which is used to determine the elemental composition of various samples.
Results: Mg levels of CA and CA+L-AIgE groups were significantly decreased compared to the control (P<0.01 for both comparisons). The mean Mg level of the CA+H-AIgE group was close to the control, and the difference was not significant. In all study groups, Se levels were significantly reduced compared to the control (P<0.05 for the CA group, P<0.01 for CA+L-AIgE and CA+H-AIgE groups). No other significant difference was detected among the groups.
Conclusion: Our study provides solid evidence of an association between CA and lower levels of Mg and Se in bones. Current data also showed that anti-IgE therapy can partially and dose-dependently prevent Mg loss induced by CA. These results have significant implications for the treatment and management of bone problems associated with asthma, highlighting the potential for anti-IgE use as a viable treatment for preventing and treating bone mineral metabolism abnormalities in asthma patients.
Primary Language | English |
---|---|
Subjects | Medical Education |
Journal Section | Original Articles |
Authors | |
Publication Date | September 15, 2023 |
Submission Date | May 16, 2023 |
Published in Issue | Year 2023 Cilt 50, Sayı 3 |